Avoid common mistakes on your manuscript.
Correction to: Rev Endocr Metab Disord (2023)
In the recently published paper, Fig. 4 should be included.
Graphic illustration of CRISPR/Cas9 genome editing for femur and cartilage repairment. Nucleic acids encoding CRISPR/Cas9 can be packaged into various viral and non-viral delivery vectors. Once packaged (A), gene editing can be carried out in vivo or ex vivo. In vivo editing can be locally administered to the patient by injecting the packaged nucleic acids into the desired/target tissue (B). Ex vivo editing includes target cells being isolated from the patient (B), which are then cultured and grown in vitro, where CRISPR components being introduced to generate the necessary modifications (C), and lastly modified cells are reimplanted into the patient (D)
Thus, this erratum is presented to fix the error.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s11154-023-09860-y.
Rights and permissions
About this article
Cite this article
Vlashi, R., Zhang, X., Li, H. et al. Correction to: Potential therapeutic strategies for osteoarthritis via CRISPR/Cas9 mediated gene editing. Rev Endocr Metab Disord 25, 451–452 (2024). https://doi.org/10.1007/s11154-023-09867-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11154-023-09867-5